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ABSTRACT
Dementia is a comprehensive category of brain diseases
that is great enough to affect a person’s daily function-
ing. The most common type of dementia is Alzheimer’s
disease, which makes most of cases. New researches
indicate that gastrointestinal tract microbiota are
directly linked to dementia pathogenesis through trig-
gering metabolic diseases and low-grade inﬂammation
progress. A novel strategy is proposed for the man-
agement of these disorders and as an adjuvant for
psychiatric treatment of dementia and other related
diseases through modulation of the microbiota (e.g. with
the use of probiotics).
KEYWORDS dementia, alzheimer’s disease, gut
microbiota, inﬂammation, probiotics
INTRODUCTION
Dementia is a syndrome that affects memory and other
cognitive functions to the extent that it interferes with daily
function. There are many conditions that can cause
dementia, including neurodegenerative disorders [e.g. Alz-
heimer’s disease (AD) and Parkinson’s disease (PD)],
cerebrovascular disease, brain injury, and certain infections.
AD is the most prevalent neurodegenerative disorder and
the leading cause of dementia worldwide, accounting for
approximately 60%–70% of all cases (Irizarry, 2001; Fra-
tiglioni, 2001). AD is a highly incapacitating disorder, pro-
gressing from minor memory problems to a complete loss of
mental functions and in the long run, resulting in death. The
symptoms of AD are caused by a progressive loss of
cholinergic function due to neuronal cell death in the hip-
pocampus cerebral cortex and different regions of the brain
which regulate thought process and memory. Furthermore,
the neuropathological hallmarks of AD consist of two kinds of
protein aggregates, amyloid beta (Aβ) plaques and hyper-
phosphorylated tangles of tau-protein. Aβ is a transmem-
brane protein which has no known function, which is con-
stitutively cleaved into peptides during the metabolic
functions of the cell (Haass et al., 1992). However, in the
case of overproduction (or impaired clearance), Aβ aggre-
gates into extracellular oligomers, ﬁbrils and eventually,
plaques (Masters et al., 1985). Whereas, tau is an intracel-
lular microtubule binding protein which, when hyper-phos-
phorylated, results in the disassembly of microtubules and
thus leads to the impediment axonal transport and compro-
mises neuronal and synaptic functions (Iqbal et al., 2005).
There are now several studies linking obesity and other
metabolic disorders with an increased risk of AD. In addition,
the inﬂammation and the pathogens interaction hypothesis
(i.e. microbial infections are causing the tau tangles and
build-up of amyloid proteins, resulting in the ensuing cell
death) were also risk factors of AD development.
The ‘gut microbiota’ can be deﬁned as all the species
within the ecosystem and are considered the largest reser-
voir of microbes in the human body, containing about
1014 microbes. Over 99% of microbiota in the GI tract are
anaerobic bacteria, with archaebacterial, protozoa, fungi,
and other microorganisms making up the remainder (Hill
et al., 2014). These GI microbiota play many important roles
in physiological homeostasis and metabolism, conferring
many health beneﬁts on the host organism, including
pathogen displacement, immune system development, bar-
rier fortiﬁcation, vitamin production and nutrient absorption,
and is often referred to as the ‛forgotten organ’ as a result of
what it is (O’Hara and Shanahan, 2006). Consequently,
there is a great deal of impetus for the comprehensive
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understanding of the complete pathological function, genetic
information and functional diversity of the gut micro-
biome that may lead to clinical AD and the discovery of
variable risk factors (Clemente et al., 2012).
In this review, we examine the roles of the gut microbiota
in the maintenance of health, inﬂammation process; and how
it is implicated in acquired metabolic diseases and aging-
related morbidity; highlighting the dementia, particularly in
AD regulation. Finally, we discuss the potential modiﬁcation
to providing clinical beneﬁt of the gut microbiome and other
methods for AD avoidance.
BRAIN-GUT AXIS
Bidirectional communications between the gut tract and the
central nervous system (CNS)—the braingut axis—occur in
both sickness and health. Recently, a role of the enteric
microbiota which count as both commensal and pathogenic
organisms (such as Biﬁdobacterium and Escherichia), in the
brain–gut axis interactions was essentially identiﬁed (Gren-
ham et al., 2011). The gut microbiota assists a number of
everyday functions in the brain, including the regulation of
the hypothalamic-pituitary-adrenal (HPA) axis activation
state. The release of cortisol as a result of HPA axis acti-
vation can in turn govern the activation state of brain
microglia, and effect cytokine release as well as attracting of
monocytes from the periphery to the brain. They also can
rule actions in the periphery and central nervous system by
various means of communication including vagal nerve and
adrenergic nerve activation as well as producing several
molecular candidates such as neurotransmitters, neuropep-
tides, endocrine hormones and immunomodulators. Host
stress hormones such as noradrenaline, which might affect
bacterial activities or signalling between bacteria, may
change the microbial diversity and actions of the gut micro-
biota. However, these bacteria are capable of synthesizing
and releasing many neurotransmitters and neuromodulators
themselves, or evoke the synthesis and release of neu-
ropeptides from enteroendocrine cells. For example: Lacto-
bacillus and Biﬁdobacterium species can produce short-
chain fatty acids; Escherichia, Bacillus and Saccha-
romyces spp. can produce norepinephrine; spore-forming
microbes can produce 5-HT; Bacillus can produce dopa-
mine, and Lactobacillus can produce acetylcholine
(Table 1) (Grenham et al., 2011; Wall et al., 2014; Potgieter
et al., 2015; Yano et al., 2015).
Dysfunction in the brain–gut microbiota axis was investi-
gated in irritable bowel syndrome, inﬂammatory bowel dis-
ease, depression, andanxiety, aswell asneurodevelopmental
disorders such as autism, Parkinson’s disease (PD), and
AD (Bonaz and Bernstein, 2013; Dinan and Cryan,
2013; Hsiao et al., 2013; Borre et al., 2014b). For example, the
recent experimental study of Holmqvist et al demonstrated
that α-synuclein, the presynaptic neuronal protein which is
abundantly expressed in the brain, was presented in PD brain
lysate and distinct recombinant α-synuclein forms were
transported via the vagal nerve and reached the dorsal motor
nucleus of the vagus in the brainstem in a time-dependent
manner after injection into the intestinal wall. The authors
indicated that different α-synuclein forms can spread from the
gut to the brain, and that microtubule-associated transport is
joined in the translocation of aggregated α-synuclein in neu-
rons (Holmqvist et al., 2014). In addition, Scheperjans et al
studied themicrobiota composition in PD patients and healthy
controls. The results suggested a signiﬁcant decrease
of Prevotellaceae in PD patients and the subjects with a lower
abundance of Prevotellaceae (<6.5% in relative abundance)
showed a higher risk of PD. In another study, the abundance
of Enterobacteriaceae was positively correlated with the
severity of PD regarding gait difﬁculty and postural instability
(Scheperjans et al., 2015).
THE ROLE OF GUT MICROBIOTA IN AD
VIA THE INFLAMMATION REGULATION
Inﬂammation is the body’s response to infections and tissue
injury and the inﬂammatory response is orchestrated by the
cells of the immune system; both from the “adaptive” branch
(including T- and B-cells with the capacity to induce long-
term memory of encountered pathogens, “immunisation”)
and the “innate” branch (including monocytes, macrophages,
dendritic cells, and mast cells, that are targeted against
common pathogen antigens). Inﬂammation was ﬁrst impli-
cated in AD pathology and development in the 1990s, with
the neuropathological ﬁnding of activated inﬂammatory cells
(microglia and astrocytes) and inﬂammatory proteins (e.g.
cytokines and complement), surrounding the amyloid pla-
ques and the neuroﬁbrillary tangles (Aisen and Davis, 1994).
In addition to the epidemiological ﬁndings, patients suffering
from arthritis and other patient groups with a high intake of
non-steroidal anti-inﬂammatory drugs (NSAID) were
observed to have had a lower proportion of individuals
affected with AD. Many of the earliest results were at ﬁrst
dismissed as inaccurate given the perception of the brain as
an “immune privileged” organ, i.e. an organ that does not
elicit inﬂammation in response to antigens or damage.
However, abundant literature can now be found in relation to
the presence of acute phase proteins in Aβ plaques, acti-
vated microglial cells that stain for inﬂammatory cytokines,
and components of the complement system in brain tissue of
AD patients. Identifying inﬂammation-associated risk factors
for AD could provide clues to the aetiology of AD and lead to
novel strategies for combating the disease (Akiyama et al.,
2000; Cacquevel et al., 2004). Since the initial discovery of a
potential inﬂammatory ingredient to the AD cocktail, studies
have diversiﬁed to look at a multitude of inﬂammation-as-
sociated risk factors for cognitive function, cognitive decline,
AD, dementia and progression in dementia; including circu-
lating inﬂammatory markers (Engelborghs et al., 1999; Yaffe
et al., 2003; Tan et al., 2007; Zuliani et al., 2007), genetic
sequence variation in immune-related genes (Arosio et al.,
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2004; Flex et al., 2004), and proxies of inﬂammatory
load (Gatz et al., 2006).
Microbiota affect the development of the gut associated
lymphoid system (GALT). The intestines contains 70% of the
body’s circulating lymphocytes, many of which are found
within the epithelium (Collins et al., 2012). In the lamina
propria there are several lines of immune cells, key to the
host response to microbiota, such as macrophages, den-
dritic cells and myoﬁbroblasts (Otte et al., 2003; Bilsborough
and Viney, 2004). Gut lymphoid tissue, and surface and
circulating immunoglobulin concentrations show a substan-
tial rise in observation of bacterial addition to the gut
(Macpherson and Harris, 2004). In the early stages of the
human life cycle, pioneering species in the gut interact
through surface cell receptors on the immune cells of the gut,
such as caspase-recruitment-domain protein (CARD), and
toll-like receptors (TLRs), to promote the expression of host
genes that generate an intraluminal and mucosal environ-
ment that further favors their colonization (Silva et al.,
1987; Hooper et al., 2001). In addition to the TLRs there is
another family of membrane-bound receptors for detection of
proteins called NOD-like receptors (NLRs). NRLs are loca-
ted in the cytoplasm and are involved in the detection of
bacterial pathogen-associated molecular patterns (PAMPs)
Table 1. The gut bacteria and their metabolites on the nervous system
Gut microbiota Metabolites
product
Effects on the nervous system function References
Lactobacillus, Biﬁdobacterium GABA Inhibitory neurotransmitter, metabolic disorders
can lead to anxiety and depression




Serotonin Neurotransmitters, regulate emotions (Shishov et al.,
2009; Özogul,
2011)
Bacillus Norepinephrine Neurotransmitters involved in motor, cognitive,





Lactobacillus, Bacillus Acetylcholine Acting on neurotransmitters in the central and
peripheral nervous systems, and cognitive













Clostridium, C. sporogenes Indole-3-
propionic
acid (IPA)










Carbohydrates (starch, cellulose, etc.), the main
products of fermentation, to provide energy for
the host, regulate endothelial cell function,
promote the synthesis and secretion of








Gram-negative bacteria Endotoxin Induced inﬂammation, release large amounts of
inﬂammatory cytokines (TNF-α, IL-6 and IL-8,
etc.), obesity, IR, diabetes and is closely
related to the occurrence of AD
















Increase the motility of the gut (Yano et al., 2015)
NOTE: GABA: gamma-aminobutyric acid; BMAA: beta-N- methylamino -L- alanine; 5-HT: 5-hydroxytryptamine; AD: Alzheimer’s disease; IR:
insulin resistance.
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that enter the mammalian cell. NRLs are especially impor-
tant in tissues where TLRs are expressed at low
levels (Philpott et al., 2001). In addition to intestinal epithelial
cells, the epithelium includes specialized cells such as
goblet cells, which secrete the protective mucus layer, lim-
iting the contact between bacteria and epithelial cells, and
Paneth cells, which reside in the crypts of the small intestine
and secrete bactericidal peptides as well as the predominant
class of immunoglobulin IgA was also found in intestinal
secretions (Cash et al., 2006). These mucosal immune
responses are lessened when exposed to heat-treated
bacteria in comparison to live organisms, suggesting that
such mechanisms involve the metabolic products of bacterial
activity as well as bacterial cell-receptor mediated sens-
ing (Macpherson and Uhr, 2004). It should be noted that it is
not only gram-negatives and lipopolysaccharides (LPS) that
can induce inﬂammation; other cell components and
metabolites can be involved, and there are also several
gram-positive pathogenic (such as Enterococcus, which is
often found as a contaminant in foods) and opportunistic
pathogenic bacteria (such as Biﬁdobacterium) that can
induce inﬂammation (Gonzalez-Navajas et al., 2008). An
endeavour searching for the connection between gut
microbiota and systemic inﬂammation showed that approxi-
mately 9% of the total variability of the microbiota was cor-
related to the pro-inﬂammatory cytokines IL-8 and IL-6 (Biagi
et al., 2010). All taxa that showed a slightly positive asso-
ciation with either IL-6 or IL-8 belonged to the phylum Pro-
teobacteria (Biagi et al., 2010). It is possible that low-grade
systemic inﬂammation constitutes a common denominator in
neurodegenerative and vascular diseases, possibly via
detrimental effects on the vasculature and leading to a
dysfunctional brain-blood barrier and inﬂammatory stimuli of
the brain. Elevated peripheral inﬂammation could also affect
brain inﬂammation by the “priming” of neurones, i.e. making
them more prone to a pro-inﬂammatory response in the
presence of tissue damage (Holmes et al., 2009). In addition,
chronic inﬂammation during foetal and childhood develop-
ment could negatively affect brain development and lower
the “cognitive reserve” (Borenstein et al., 2006).
The researchers noted that the affected AD brains are
largely inﬂamed, glial cells rushing to the brain regions that
become ill and trying to clean up waste products from cells
and plaque, but once up to this area, they in fact are urged to
liberate more Aβ harmful, precipitate in the formation of
plaque, which attracts more accurate glial cells, and so
on. According to Balin et al and other studies, amyloid pro-
teins play a part in the disease, but only in response to the
initial inﬂammation caused by the microbial infection, that is
attacking the brain (Balin and Hudson, 2014). Recent study
showed that Aβ may play a protective role in innate immunity
and infectious or sterile inﬂammatory stimuli may drive
amyloidosis and that Aβ oligomerization, a behavior tradi-
tionally viewed as intrinsically pathological, may be neces-
sary for the antimicrobial activities of the peptide, which
mean that Aβ serves to protect the brain from invading
microbes (Kumar et al., 2016). In vitro study of Chlamydia
pneumoniae showed that the infection of monocytes could
stimulate innate and adaptive immune responses relevant to
those in AD (Balin and Hudson, 2014; Lim et al., 2014; Little
et al., 2014). Hoban et al, elucidated the mechanisms of the
microbial inﬂuence by investigating changes in the homeo-
static regulation of neuronal transcription of germ-free mice
within the prefrontal cortex, and showed that the microbiome
is necessary for appropriate and dynamic regulation of
myelin-related genes (the formation of fatty sheathing that
insulates nerve ﬁbres), with clear implications for corti-
cal myelination at an ultrastructural level (Hoban et al.,
2016). Experiments by Lee et al also showed that the germ-
free mice were protected from causing the case experi-
mentally, similar to multiple sclerosis, characterized by the
demise of myelin, which encases nerve ﬁbers (Lee et al.,
2011). There is also the possibility that these hypothetical
pathways are tangled and that e.g. Aβ deposits in the
cerebrovascular wall will elicit a peripheral inﬂammatory
response that will in turn enhance brain inﬂammation
(Fig. 1).
PUTATIVE ROLE OF MICROBES’ PRODUCTS
The dysfunction of the gut epithelial barrier resulting from
dysregulation of the brain–gut -microbiota axis could pro-
mote invasion of neuroactive substances, including neu-
rotropic viruses, unconventional pathogens with prion–like
properties, or slow neurotoxins (Hawkes et al., 2007). Some
microbes can remain latent in the body with the potential for
reactivation, the effects of which might happen years after
early infection; and that people can be infected but not
necessarily affected, such that ‘controls’, even if infected, but
with symptoms (Itzhaki, 2014). It is remarkable that human
microorganisms that produce amyloids such as CsgA, Aβ42,
and other peptides that accrue in AD brains (Hill and Lukiw,
2015). For example, amyloids are related to fungal surface-
structures and the new statement of amyloidogenic fungal
proteins and diffuse mycoses in the blood of AD patients
suggest that chronic fungal infection associates with high
risk of AD (Hill et al., 2014). Moreover, Escherichia coli pro-
duce extracellular amyloids known as curli ﬁbers, composed
of the major structural sub-unit CsgA, are a common
secretory component that facilitate surface adhesion, bioﬁlm
development and protection against host defen-
ces (Schwartz and Boles, 2013). A number of bacterial
amyloid systems include Pseudomonas, Streptomyces,
Staphylococcus, Bacillus, and others, propose that func-
tional amyloids are an extensive phenomenon used by a
wide diversity of microbiomes (Schwartz and Boles,
2013; Hill et al., 2014). Furthermore, bacterial enzymes may
also produce neurotoxic metabolites such as D-lactic acid
and ammonia (Galland, 2014). The direct neural communi-
cation between the gut and the brain occurs via the vagal
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nerve, as bacteria can stimulate afferent neurons of the
enteric nervous system (ENS) (Forsythe et al., 2014). Vagal
signals from the gut could also induce an anti-inﬂammatory
reaction to protect the body from the infections caused by
pathogens in a nicotinic acetylcholine receptor α7 sub-unit
dependent manner (Grenham et al., 2011; Borre et al.,
2014a; Forsythe et al., 2014; Mulak and Bonaz, 2015).
Additionally, other human gut-resident Cyanobacteria-gen-
erated neurotoxins including β-N-methylamino-l-alanine
(BMAA), saxitoxin, and anatoxin-α may further contribute to
neurological diseases as amyotrophic-lateral sclerosis
(ALS), the Parkinson-dementia complex of Guam, and AD
especially over the course of aging (Brenner, 2013; Lakhan
et al., 2013; Tran and Greenwood-Van Meerveld,
2013). Parodi et al demonstrated that rosacea patients have
a signiﬁcantly higher small intestinal bacterial overgrowth
(SIBO) prevalence than controls, The effectiveness of SIBO
eradication in rosacea may recommend that these bacteria
play a role in the pathogenesis of rosacea lesions(Parodi
et al., 2008). Moreover, patients who have rosacea are at
increased risk of developing dementia, particularly AD (Nurs-
ing-Standard, 2016).
GUT MICROBIOTA AND METABOLIC DISEASES
High-fat diets and sedentary lifestyles have become major
concerns throughout the world. The morbid conditions rela-
ted to obesity such as abdominal obesity, insulin resistance
and glucose intolerance, hypertension and dyslipidemia are
together called the metabolic syndrome. Obesity and its co‐
associated morbidities, namely cardiovascular disease
(CVD), type‐2 diabetes mellitus (T2DM), fatty liver disease
and hypertension are a great economic burden in affected
countries. Of note, accumulating evidence suggests a
mechanistic relation between the cholesterol metabolism in
the brain and the formation of Aβ plaques in AD develop-
ment (Martins et al., 2006). High blood sugar and body fat
can place you at a higher risk for AD and blood restric-
tion. Metabolomics study by Dumas et al suggested that gut
microbiota may also play an active role in the development
of complex metabolic abnormalities, such as susceptibility to
insulin resistance and fatty liver disease (Dumas et al.,
2006). Subsequent analysis of germ-free versus conven-
tional mice on high-fat diet revealed that both insulin sensi-


















































Figure 1. Schematic of some key players in the pathogenesis of AD. The gut microbiota regulation of neuro-inﬂammation and
the hypothalamic–pituitary–adrenal (HPA) axis activity and may lead to AD. The bacterial products that gain access to the brain
through the bloodstream and the area postrema, via cytokine release from mucosal immune cells, through the release of gut
hormones such as 5-HT from EEC cells, or via afferent neural pathways, including the vagal nerve. NP: Neuropeptide; NT:
Neurotransmitter; 5-HT: 5-hydroxytryptamine; DC: Dendritic cell; EEC: Enteroendocrine cell; Aβ: amyloid beta protein; AD:
Alzheimer’s disease.
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inﬂuenced by the gut microbiota (Rabot et al., 2010). Com-
plementary clinical studies further demonstrated that raised
circulating levels of the gut microbiota metabolite within
subjects predicted increased cardiovascular danger inde-
pendent of traditional cardiovascular risk factors (Wang
et al., 2011). Increasingly, the role of CVD is also being
recognized as an important etiologic hallmark of AD. Indeed,
many studies were summarized ﬁndings on CVD and risk
factors in the aetiology of AD and showed the importance of
vascular pathology in AD (Jagust, 2001; de la Torre,
2004; de Bruijn and Ikram, 2014). Consequently, there is an
increasing number of proofs suggesting that gut microbiota,
through a variety of processes, can inﬂuence physiological
processes important for the development of CVD (Hazen
and Smith, 2012).
OBESITY INCREASES THE RISK OF COGNITIVE
IMPAIRMENT OR MENTAL DECLINE
It is generally believed that gut microbiota control obesity, the
major cause of T2DM, which has recently been linked with AD
development (Pasinetti et al., 2011). Recent studies have also
found the role of gut microbiota in the control of brain function
directly by tryptophan metabolism, production of microbial
metabolites, microbial neurotransmitters and bacterial cell
wall sugars and bile acids (Swann et al., 2011; Collins et al.,
2012; Tremaroli and Backhed, 2012). Tremaroli et al found
conclusive evidence that gut microbiota could inﬂuence the
activity of lipoprotein lipase (LPL) -the key enzyme involved in
the release of fatty acids from triglyceride-rich lipoproteins in
muscle, heart, and fat- by affecting the expression of fasting-
induced adipocyte factor protein (FIAF)—key inhibitor of LPL
activity and plays an important role in preventing obesity- that
was over expressed in the germfree mice and reduce storage
of triglycerides in the adipose tissue (Tremaroli and Backhed,
2012). Upregulation of adipocyte LPL activity leads to
increase cellular uptake of fatty acids and adipocyte triglyc-
eride accumulation. Consequently, suppression of intestinal
FIAF by microbes promotes adiposity through upregulation of
LPL activity in adipocytes and increased hepatic lipogenesis
were found to enhance the accumulation of calories har-
vested from the diet into fat then storage in the liver, which is
the main cause of insulin resistance in obesity (Fig. 2).
Moreover, speciﬁc bacterial taxa of the gut microbiota are
involved in nutrient uptake and energy homeostasis and may
lead to low grade inﬂammation induced by LPS, causing
activation of the innate immune response. This low grade
inﬂammation is connected to low, but constant levels of LPS
in the circulation and to increased levels of adiposity and
insulin resistance (obesity and T2DM) (DiBaise et al., 2008).
Additionally, previous literature demonstrated that ileal
inﬂammation, decreased LPS activity, and increased innate
immune system activation was observed in rats susceptible to
weight gain as compared to the obesity resistant rats (de La
Serre et al., 2010).
TYPE-3 DIABETES
New evidence has come to light concerning the different
expressions of diabetes, as well as its connection to other
diseases. It used to be supposed that there were two types
of diabetes: type-1 and type-2. However, the idea that AD
might be type-3 diabetes was proposed ten years ago (Mar-
tins et al., 2006). Some studies suggested that AD pro-
gresses because of the brain developing resistance to
insulin, which in turn prevents proper lipid uptake. Over time,
these lipids build up in the brain rather than properly absorb,
which results in increased stress and inﬂammation, as well
as the symptoms usually related with dementia (de la Monte,
2014; Rani et al., 2016). Given the evidence provided by
T2DM Obesity
Metabolic syndrome







Figure 2. The links between gut microbiota and
metabolic diseases, as obesity and further develop-
ment of T2DM with AD. FIAF: fasting-induced adipocyte
factor; LPS: lipopolysaccharide; LPL: lipoprotein lipase;
T2DM: type 2 diabetes mellitus; AD: Alzheimer’s disease.
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animal models of the strong relationship between T2DM and
AD. When the authors blocked the path of insulin to rats’
brains, their neurons deteriorated, they became physically
confused and their brains showed all the signs of AD. Fur-
thermore, the study provided proof that T2DM and AD
aggravate each other and suggested several potential
mechanisms underlying the two disorders, such as, Aβ
clearance by insulin degradation enzyme (IDE), glucose
metabolism, O-GlcNAcylation, Aβ aggregation by advanced
glycation end products (AGEs), oxidative stress, circulating
cortisol, and cerebral vascular insufﬁciency, as well as
inﬂammation, and aging. In fact, people with diabetes have
double the risk of developing AD. This does not mean that
everyone who has diabetes will eventually develop AD, or
that all people with AD have diabetes. It is important to report
that there is an important link between diabetes and AD, and
it is therefore common that pathophysiology probably con-
stitutes a major underpinning of late-onset sporadic AD, and
a novel therapeutic approach targeting this pathological
process could contribute to the development of a more efﬁ-
cient and effective treatment for AD (Park, 2011; de la Monte,
2014).
AGING
Alzheimer’s cases show a dramatic increase with age,
affecting about 1% of the population aged between 65-69
years up to 30-40% in the oldest individuals (Gatz et al.,
2006). Overall occurrence in the population above 65 years
of age is estimated to 6-8% and is expected to increase
signiﬁcantly worldwide due to changing demographic proﬁles
with an ever-increasing proportion of elderly (Ferri et al.,
2005). Indeed, as adulthood approaches, the gut microbiota
stabilizes, becomes more diverse, and can resist detrimental
environmental elements such as antibiotics and stress by
restoring its diverse and stable ‘normal’ core micro-
biota (Palmer et al., 2007; Rajilic-Stojanovic et al., 2011).
However, as we age, the diversity and stability of our
microbiota will decline (Biagi et al., 2010), moreover there is
an associated increase in number, size and activation of
microglia that can lead to an increased inﬂammatory tone
named ‘inﬂammaging’ (Franceschi, 2007; von Bernhardi
et al., 2015). There is high heterogeneity of microglia in
several neurodegenerative diseases, including AD and
those phenotypes share common characteristics with aging
(Bachstetter et al., 2015). In normal aging, close crosstalk
with astrocytes, neurons and other brain cells serve crucial
functions as the scavenger system of the CNS, providing
beneﬁcial functions such as tissue repair in the CNS. How-
ever, chronic, dysregulated activation of microglia can lead
to elevated inﬂammatory tone ultimately resulting in the
malfunction or damage of brain cells. The role of the
microbiota in addition to what drives this dysregulation has
yet to be fully understood.
AD MICE AND GUT MICROBIOTA
A recent experimental study conducted by Harach et al
observed marked differences of the gut microbiota compo-
sition between aged AD mice and healthy WT mice and
strongly advocated that a distinct microbial constitution in AD
mice may play a role in the development of cerebral Aβ
amyloidosis (Harach et al., 2015). In this study, the authors
demonstrated that the abundance of the two major phyla
(Firmicutes andBacteroidetes) in the fecal microbiota is
dramatically altered by host genetics. At genus level, Al-
lobaculum and Akkermansia were decreased in transgenic
CONVR-APPPS1 mice and unclassiﬁed genera of Rikenel-
laceae and S24-7 were increased. Reduced levels
of Akkermansia have been associated with obesity and type
2 diabetes in mice (Everard et al., 2013), and the prebiotic-
induced restoration of Akkermansia in the gut resulted in a
lower fat-mass gain and decreased systemic inﬂammation
(two discussed risk factors in the development of AD
pathology). Furthermore, the relative abundance of several
bacterial genera was correlated with the amount of soluble
Aß42 in the brain (Harach et al., 2015).
DELAY THE PROCESS OF NEURODEGENERATION
Probiotics and prebiotics
The increased understanding of the impact of the gut
microbiota on human health resulted in attempts to
manipulate its composition by the use of probiotics and
prebiotics, from both prophylactic and therapeutic per-
spectives. Probiotics are deﬁned as live microbial organ-
isms that, when consumed in adequate quantities, confer
health beneﬁts to the host (Berg, 1998). Prebiotics are
chemical substances, usually oligosaccharides, acting as
substrates speciﬁcally for the host’s autochthonous probi-
otic bacteria, and thus promoting their growth. Prebiotics
are selected as being non-digestible by the host and non-
metabolizable by non-probiotic gut bacteria, but stimulating
for biﬁdobacteria and lactobacilli (Gibson et al.,
2004; Hamilton-Miller, 2004). A food is considered synbiotic
when it contains a prebiotic and a probiotic ingredient. The
species Lactobacillus, Biﬁdobacterium and Streptococ-
cus are the most commonly studied to date because they
are common and are ‘natural’ members of the intestinal
microbiome (Gordin and Gorbach, 1992; Berg, 1998).
Moreover, these bacteria do not necessarily need to be
alive, as products of the bacteria, such as cell walls and
bacterial DNA, can modulate the proﬁle of the gut micro-
biota and immune responses (Agostoni et al., 2004; Thi-
bault et al., 2004). Their main beneﬁcial effects are to
function as the ﬁrst barrier to pathogenic organisms by
adherence, to produce substances that have antimicrobial
effects, and to stimulate the immune processes in the
host (Floch, 2005; Chermesh and Eliakim, 2006). Further-
more, certain strains of lactic acid bacteria (LAB) produce
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the complex vitamin cobalamin (or vitamin B12) which
directly associated with AD, based on many of the studies
which showed that vitamin B12 levels are lower in AD
individuals compared with healthy subjects (LeBlanc et al.,
2013; Chen et al., 2015). Additionally, fermented milks with
high levels of B-group vitamins (such as folate and ribo-
ﬂavin) can be produced by LAB-promoted and possibly Bi-
ﬁdobacteria-promoted biosynthesis (LeBlanc et al.,
2013). As the pathogenesis of different diseases is diverse,
the mechanisms by which bacteria effect disease pro-
cesses are unique. All the same, probiotic development
shows great capacity for rebuilding microbiotas and
restoring health, especially for some individuals. Therefore,
the practical application portability of species beneﬁcial in
one illness will not necessarily hold for another. As for the
prebiotics, inuline supplementation was reported to be able
to increase the viable count of biﬁdobacteria in constipated
elderly, while the frequency of the detection of enterobac-
teria decreased with the treatment. The ingestion of inuline
improved constipation in 9 out of 10 subjects (Kleessen
et al., 1997). It was reported that fructo-oligosaccharide
ingestion (Guigoz et al., 2002; Bouhnik et al., 2007), as well
as the supplementation of a galacto-oligosaccharide mix-
tures are able to signiﬁcantly increase the numbers of biﬁ-
dobacteria at the expense of less beneﬁcial groups (Vulevic
et al., 2008).
NSAIDs
Several epidemiological studies suggested that NSAIDs may
delay the onset of AD for up to ﬁve or more years, and are
even able to prevent the onset of AD in patients with mild
cognitive impairment (MCI) or in healthy elderly subjects at
risk of developing AD (Imbimbo et al., 2010). Thus, it could
be hypothesized that the chronic use of NSAIDs may be
beneﬁcial only in the very early stages of the AD process in
coincidence of initial Aβ deposition, microglia activation and
consequent release of pro-inﬂammatory mediators. When
the Aβ deposition process is already started, NSAIDs are no
longer effective and may even be detrimental because of
their inhibitory activity on chronically activated microglia that
on long-term may mediate Aβ clearance (Imbimbo et al.,
2010). In conclusion, these studies indicate that there is a
dose-response relationship between NSAID use and the
relative risk of AD, with longer periods of use related to
reduce relative risks of AD. Based on these studies, the
relative risk of AD appears to be 25-50% lower in groups of
individuals with long-term (2 years or more) NSAID use (in t’
Veld et al., 2001). The reduction in risk also appears to be
restricted to AD; no protective effect against vascular
dementia was noted. The hypothesis is that the inﬂammatory
response to the accumulating Aβ and tau deposits worsens
the pathological process and that NSAIDs may alleviate the
process by inhibiting the inﬂammatory response and/or
inhibiting glutamate toxicity (Casper et al., 2000; Imbimbo
et al., 2010).
Grape seed
Grape seed polyphenol extract (GSPE) was widely consid-
ered a dietary supplement with widespread health beneﬁts.
Many studies recently demonstrated the potential efﬁcacy of
GSPE in protecting against neuropathology and cognitive
impairment in animal models of AD and tau-mediated neu-
rodegenerative disorder (Wang et al., 2008; Santa-Maria
et al., 2012). The growing body of experimental, preclinical,
and clinical evidence supporting GSPE exerting beneﬁcial
biological activities in multiple medical conditions, has led to
increased interest in its bioavailability, metabolism, and dis-
tribution of the primary GSPE phenolic constituents, includ-
ing gallic acid, epicatechin, proanthocyanidin dimers, and
larger oligomers. Interestingly, evidence suggests that
intestinal microbiota signiﬁcantly contribute to GSPE meta-
bolism/absorption, as catechin and epicatechin, major com-
ponents of GSPE, are both metabolized by colonic
microbiota fermentation (Aura et al., 2002; Cueva et al.,
2013). Wang et al demonstrated that intestinal microbiota
may contribute to the protective activities of GSPE in neu-
rodegenerative disorders, and in other diseases, by con-
verting proanthocyanidin components from GSPE to
phenolic acid metabolites capable of accumulating in target
tissues, such as the brain, and of exerting disease-modifying
activates (Wang et al., 2015). Table 2 summarize the
methods described above.
Critical challenges
During the last three decades, Alzheimer’s research has not
only made remarkable progress in understanding the dis-
ease but also has recruited some of the best scientists in the
world. The prospect of delaying or preventing the onset of
symptoms is feasible and within our grasp. However, this
mission must surmount a number of barriers, which contain
inadequate funding of research, high cost of clinical studies,
lack of suitable infrastructure, better models, antiquated
administrative structure of discovery programs, and arcane
decision-making systems for selecting and funding innova-
tive ideas. Recently, the only way to know for certain that
someone has AD is to examine an autopsy of their brains
tissue after death. The crucial challenge for the AD resear-
ches is how to understand the process of neurodegenerative
disorders throughout the patient’s lifetime. Additionally, the
lack of efﬁcient cultivation techniques stems from many
factors that largely remain unknown (Lopez et al., 2015).
Hence, molecular ecology and metagenomics have signiﬁ-
cantly increased our knowledge of the genetic diversity and
have led to interesting hypotheses (Hugenholtz and Tyson,
2008). The advanced techniques have also revealed how far
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we are from measuring the full extent of genetic diversity
encoded by microbial life (Hugenholtz and Tyson,
2008; Pignatelli et al., 2008).
SUMMARY
Microbial colonization of the gut plays a key role in the
postnatal development and maturation of the immune,
endocrine and even neural systems, these processes are
key factors underpinning CNS signalling. Indeed, under-
standing the gut microbiota is important in relation to
inﬂammation and metabolic diseases that have a direct
relation to the AD pathogenesis. Moreover, comparative
analysis of gut microbiota may enable further novel vision
into the complex biology of AD, which is very important in
order to take preventive measure such as early diagnosis,
identiﬁcation of new therapeutic targets and development of
novel drugs. Thus, modulation of gut microbiota (by probi-
otics or other dietary intervention) or direct targeting of gut
microbiota enzymes (by pharmacological inhibitors or acti-
vators) may be a growing area for pharmaceutical and
functional food industries, with the goal of decreasing the
widespread growth of adiposity, insulin resistance, AD, and
other metabolic diseases.
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ABBREVIATIONS
Aβ, amyloid beta; AD, Alzheimer’s disease; AGEs, advanced
glycation end products; ALS, amyotrophic-lateral sclerosis; BMAA,
β-N-methylamino-l-alanine; CARD, caspase-recruitment-domain
protein; CNS,central nerve system; CVD, cardiovascular disease;
ENS, enteric nervous system; FIAF, fasting-induced adipocyte factor
protein; GALT; gut associated lymphoid system; GSPE, Grape seed
polyphenol extract; HPA, hypothalamic-pituitary-adrenal; IDE, insulin
degradation enzyme; LAB, lactic acid bacteria; LPL, lipoprotein
lipase; LPS, lipopolysaccharide; MCI, mild cognitive impairment;
NLRs, NOD-like receptors; NSAIDs, non-steroidal anti-inﬂammatory
drugs; PD, Parkinson’s disease; SIBO, higher small intestinal
Table 2. Some methods that using to delay the process of neurodegeneration
Products Description Components Foods contain them
Probiotic Live microorganisms confer a health beneﬁt














Prebiotic Chemical substances, nondigestible foods
that make their way through our digestive
system and help good bacteria grow and





Bananas, Onions, Garlic, Leeks,
Asparagus, Whole wheat, Barley,
Rye, Inuline
NSAIDs A drug class that groups together drugs:
provide analgesic (pain-killing)
and antipyretic (fever-reducing) effects,







Broccoli, Cauliﬂower, Cherries, Chili
peppers, Cucumbers, Dates,
Eggplant, Figs…
GSPEf An industrial derivative of whole grape seeds







a Kombucha—slightly effervescent drink that is brewed with tea and sugar and fermented into a liquid. This beverage originated in China nearly
2000 years ago.
b Kimchi—a traditional Korean lacto—fermented condiment made from cabbage.
c Miso is made by adding an enzymatic culture to a soybean base and often a grain.
d Sauerkrautis cabbage that has been salted and lacto-fermented over a period of weeks.
e Inulin is a natural prebiotic ﬁber that is found in over 36,000 plants worldwide.
f GSPE—grape seed polyphenol extract.
REVIEW Rashad Alkasir et al.









bacterial overgrowth; T2DM, type‐2 diabetes mellitus; TLRs, toll-like
receptors
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